Thanks to technological advances, the past several decades have witnessed a blossoming appreciation of the varied composition of these microbial communities, their complex and dynamic relationship with the host, and the way they affect health and disease.
Byrne Lee, MD, discusses regional treatment strategies for patients with metastatic colorectal cancer.
Marwan Fakih, MD, discusses recent trials in colorectal cancer and highlights other ongoing research in the field.
Because specific risk-reducing interventions may be available, it is important to identify individuals with germline variants in cancer susceptibility genes.
Pashtoon M. Kasi, MD, MBBS, MS, provides an overview of the potential for liquid biopsies in CRC and advances being made in the treatment landscape.
Michael J. Overman, MD, highlights new combination agents under investigation for the treatment of patients with GI cancers—specifically CRC—and challenges that still need to be addressed.
The FDA has cleared a direct-to-consumer genetic test for a risk report on MUTYH-associated polyposis, a hereditary colorectal cancer syndrome.
Tanios Bekaii-Saab, MD, discusses ways to further develop precision medicine within the treatment of patients with gastrointestinal cancers.
The combination use of durvalumab and tremelimumab plus best supportive care prolonged median overall survival by 2.5 months compared with supportive care alone in patients with advanced refractory colorectal cancer.
The PD-L1 inhibitor durvalumab achieved objective responses in about a fourth of patients with microsatellite instability-high advanced solid tumors, including colorectal cancer.